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ABSTRACT 
 
Two activating mouse IgG receptors (FcγRs) have the ability to bind monomeric IgG, 
the high-affinity mouse FcγRI and FcγRIV. Despite high circulating levels of IgG, reports 
using FcγRI-/- or FcγRIV-/- mice or FcγRIV-blocking antibodies implicate these receptors in 
IgG-induced disease severity or therapeutic Ab efficacy. From these studies, however, one 
cannot conclude on the effector capabilities of a given receptor, because different activating 
FcγRs possess redundant properties in vivo, and cooperation between FcγRs may occur, or 
priming phenomena. To help resolve these uncertainties, we used mice expressing only FcγRI 
to determine its intrinsic properties in vivo. FcγRIonly mice were sensitive to IgG-induced 
autoimmune thrombocytopenia and anti-CD20 and anti-tumour immunotherapy, but resistant 
to IgG-induced autoimmune arthritis, anaphylaxis and airway inflammation. Our results show 
that the in vivo roles of FcγRI are more restricted than initially reported using FcγRI-/- mice, 
but confirm effector capabilities for this high-affinity IgG receptor in vivo. 
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1. INTRODUCTION 1 
 2 
 IgG receptors (FcγR) in both humans and mice are divided into high-affinity IgG 3 
receptors that are able to retain monomeric IgG, and low-affinity IgG receptors that do not. Both 4 
high- and low-affinity FcγRs are, however, able to bind to IgG-immune complexes or IgG-5 
opsonised cells and surfaces. In humans only hFcγRI is a high-affinity IgG receptor, for human 6 
IgG1, IgG3 and IgG4; and in mice both mFcγRI (for mouse IgG2a) and mFcγRIV (for mouse 7 
IgG2a and IgG2b) are high-affinity receptors [1]. Although it was proposed that high-affinity 8 
FcγRs are occupied by circulating IgG in vivo (discussed in [2]), multiple effector roles for 9 
hFcγRI, mFcγRI and mFcγRIV have been reported using mouse models of disease and therapy 10 
[3-6]. 11 
hFcγRI has been studied by exogenous expression in hFcγRItg mice, demonstrating its 12 
role on dendritic cells in the enhancement of antigen presentation and cross-presentation [7], and 13 
on neutrophils and monocyte/macrophages in inflammation, autoimmunity and systemic 14 
anaphylaxis [8].  These studies indicate that hFcγRI can, by itself, induce clinical signs of 15 
autoimmune diseases, by triggering local inflammation (e.g. autoimmune rheumatoid arthritis) or 16 
phagocytosis (e.g. autoimmune thrombocytopenia and anaemia [9]). Additionally, hFcγRI was 17 
reported to induce allergic shock (anaphylaxis) triggered by IgG-immune complexes [8]. Finally, 18 
hFcγRI may also be a therapeutic target as it can mediate antibody-based therapies such as anti-19 
malaria [10], anti-metastatic melanoma [8] and angiogenesis prevention [6]. The mouse 20 
counterpart of hFcγRI, mFcγRI, has been so far studied only by the effect of its absence. 21 
Compared to wild-type, mFcγRI-/- mice demonstrate reduced reaction severity in models of 22 
autoimmune diseases such as experimental haemolytic anaemia and arthritis [11, 12]. In addition 23 
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mFcγRI-/- mice are less susceptible to IgG-mediated systemic anaphylaxis, Arthus reactions [13, 24 
14], and show reduced efficacy of anti-melanoma [15-17], anti-lymphoma [18] and anti-25 
angiogenic therapies [6]. mFcγRIV was also initially studied by its absence in mFcγRIV-/- mice 26 
or by using blocking anti-mFcγRIV mAbs. These studies reported reduced IgG-mediated 27 
autoimmune anaemia, thrombocytopenia, rheumatoid arthritis and experimental nephrotoxic 28 
nephritis, but also reduced anaphylaxis and less efficient subcutaneous melanoma therapy in the 29 
absence or after blockade of mFcγRIV [19, 20]; some of the latter results should be taken with 30 
caution since mFcγRIV-blocking antibody 9E9 may also block mFcγRIII in vivo [21]. Effector 31 
functions could nevertheless be definitively attributed to mFcγRIV through the generation of 32 
mice expressing mFcγRIV without other FcγR. Indeed, using mFcγRIVonly mice we could 33 
demonstrate that mFcγRIV can individually induce autoimmune thrombocytopenia and 34 
rheumatoid arthritis, as well as IgG-mediated airway inflammation and anaphylaxis, but not anti-35 
metastatic melanoma therapy [8, 22-24]. Altogether these data propose multiple effector 36 
functions for high-affinity receptors hFcγRI, mFcγRI and mFcγRIV in autoimmune and 37 
inflammatory disease models, and therapy, with direct evidence provided by studies using 38 
hFcγRItg mice and mFcγRIVonly mice, but only indirect evidence provided by mFcγRI-/- mice. 39 
The in vivo effector functions proposed for mFcγRI in IgG-mediated autoimmune disease 40 
and therapy models are surprising, considering its expression is restricted to monocytes, 41 
monocyte-derived dendritic cells and some tissue-resident macrophages, and is absent on 42 
neutrophils. As several reports suggest redundant functions among mFcγRs (reviewed in [1, 2]), 43 
it is uncertain if mFcγRI can induce IgG-mediated autoimmune diseases and therapeutic efficacy 44 
by itself, or if this receptor is indirectly involved: either for optimal activation via other mFcγRs 45 
or priming of effector cells. Therefore we analysed the in vivo effector functions of mFcγRI in 46 
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mFcγRIonly mice, i.e. in the absence of mFcγRIIB, mFcγRIII and mFcγRIV, in comparison with 47 
mFcγRnull mice that express no mFcγR. Our results identify the effector functions of mFcγRI as 48 
more restricted than initially reported, but confirm that mFcγRI does function independently in 49 
vivo, in particular for depletion of IgG-opsonised cells. 50 
   51 
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2. MATERIALS & METHODS 52 
2.1 Mice 53 
C57BL/6J mice (WT) were purchased from Charles River. VG1505 (FcγRIonly) mice were 54 
reported previously [17] and generated by Regeneron Pharmaceuticals, Inc. FcγRnull mice were 55 
generated by crossing FcγRIonly mice to FcγRI-/- mice. FcγRIonly and FcγRnull mice were bred at 56 
Institut Pasteur, used for experiments at 8-11 weeks of age and all protocols were approved by 57 
the Animal Ethics committee CETEA (Institut Pasteur, Paris, France) registered under #C2EA-58 
89. 59 
 60 
2.2 K/BxN serum-induced passive arthritis  61 
K/BxN serum was generated from a pooled collection of >40 animals. Arthritis was induced by 62 
i.v. transfer of indicated volumes of K/BxN serum, and scored as described [25]. In some 63 
experiments mice were sacrificed on day 8 for blinded histological assessment. 64 
 65 
2.3 Airway Inflammation 66 
As previously described [26], mice were injected with 50 µL of rabbit anti-OVA serum i.n. and 67 
500 µg of OVA i.v. 16-18h later 4 bronchoalveolar lavages (BALs) were performed with cold 68 
PBS (1x 0.5ml, then 3x 1mL) under lethal anaesthetic. Cells were pooled and stained for flow 69 
cytometry after RBC lysis; and haemorrhage was determined by OD570nm in the supernatant. 70 
We confirmed that mFcγRI, like all mouse FcγR, can indeed bind rabbit IgG immune complexes 71 
(Supplementary Fig.2). 72 
73 
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2.4 Passive Systemic Anaphylaxis (PSA) 74 
Mice were sensitised by i.v. injection of 500µg anti-DNP IgG2a (clone Hy1.2) and challenged 75 
16h later with 200µg TNP(21-31)-BSA i.v. Alternatively, mice were injected with 1mg of heat-76 
aggregated (1 hour at 63°C in BBS pH8) human IVIG; considering that mouse FcγRI cross-binds 77 
human IgG subclasses 1, 3 and 4 [27]. Central temperature was monitored using a digital 78 
thermometer with rectal probe (YSI). 79 
 80 
2.5 Experimental Thrombocytopenia 81 
Blood samples were taken in EDTA before and at indicated time points after i.v. injection of 3 or 82 
10µg anti-platelet mAb 6A6. Some mice were treated 32h before 6A6 injection with 300µL PBS- 83 
or clodronate- liposomes i.v. Platelet counts were determined using an ABC Vet automatic blood 84 
analyser (Horiba ABX). 85 
 86 
2.6 Tumour Immunotherapy 87 
Mice were depilated and received 5x105 B16-Luc2+ cells s.c. on d0. Where indicated, mice were 88 
injected i.v. with 200µg mAb TA99 on d1, d2 and d3 (Figure 4A, closed symbols), and control 89 
groups were untreated (Figure 4A, open symbols). Bioluminescence was acquired from 90 
anaesthetised mice on d1, d7 and d13, 10 min after injection of 75µg luciferin s.c. (IVIS 91 
Spectrum CT, Caliper Life Sciences), and images were analysed with Living Image software. 92 
 93 
2.7 Anti-mouse CD20 treatment 94 
Mice received a single i.v. injection of 50µg anti-mouse CD20 (clone 5D2, IgG2a, Genentech) to 95 
deplete endogenous B cells, or saline control, and CD19+B220+ B cells in the blood, spleen and 96 
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inguinal lymph nodes were assessed 16 hours later by flow cytometry. Remaining B cells were 97 
calculated as a percentage of the average of vehicle-treated controls (Fig. 4B). 98 
 99 
2.7 Statistics 100 
Data was analysed using one-way ANOVA with Bonferroni post-test (Fig.2C) or a Tukey’s  101 
multiple comparisons test (Fig.1 B) to compare individual timepoints (Fig.2 B, D & E, and Fig.3 102 
A, B & E), or a Kruskal-Wallis test with Dunn’s multiple comparisons (Fig. 2A & 2C, bottom 103 
panel); a Student’s t-test (Fig.3 C&D, Fig.4B) or a Mann-Whitney test (Fig.4A). Statistical 104 
significance is indicated (ns: p>0.05; *p<0.05; **p<0.01, *** p<0.001, **** p<0.0001). 105 
 106 
Please refer to supplemental Methods for information on reagents, flow cytometry, histology, 107 
surgical procedures and Active Systemic Anaphylaxis (ASA). 108 
 109 
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3. RESULTS & DISCUSSION 110 
 111 
 To evaluate the in vivo effector functions of mouse FcγRI, we investigated mice 112 
expressing this receptor in the absence of other endogenous classical FcγR (FcγRIIB, FcγRIII and 113 
FcγRIV-deficient), termed FcγRIonly mice [17] or VG1505 mice [28], in comparison with mice 114 
deficient for all four endogenous classical FcγRs (FcγRI, FcγRIIB, FcγRIII and FcγRIV-115 
deficient), termed FcγRnull mice (Fig.1A). Both strains retain FcRn and non-classical IgG receptor 116 
expression. FcγRIonly and FcγRnull mice display normal breeding patterns and development, and 117 
no overt pathological signs up until 1 year of age. We assessed the circulating immune cell 118 
populations in these novel strains, compared to WT mice, using an automated blood cell analyser 119 
(Fig.1B). Across a large sample size, WT, FcγRIonly and FcγRnull mice display comparable total 120 
leukocyte counts in the blood, and similar frequencies of leukocytes, granulocytes and 121 
eosinophils (Fig.1B). Notably, FcγRIonly and FcγRnull mice have a slightly higher frequency of 122 
circulating monocytes. The pattern of expression of FcγRI in FcγRIonly mice was comparable to 123 
wt mice: FcγRI was detected on circulating Ly6Chi and Ly6Clow monocytes (Fig.1D), with greater 124 
expression on the latter, and on CD11b+CD11c+ spleen cells, liver kupffer cells and liver 125 
macrophages, alveolar macrophages and bone marrow monocytes (not shown) and prominently 126 
on CD11b+ skin resident cells (Fig.1E), but barely detected on F4/80+ peritoneal macrophages, in 127 
agreement with previous reports [24, 29, 30].  128 
 129 
An understanding of the participation of FcγRI in autoimmune and inflammatory 130 
pathologies remains elusive [4]. FcγRI-/- mice seem to experience reduced inflammation 131 
associated with immune complex tissue deposition [13] and severity of antigen-induced arthritis 132 
[11, 12]. Yet redundancy between FcγRI and FcγRIII certainly exists [12] and many of these 133 
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earlier studies did not consider the potential contribution of FcγRIV [14, 24]. To address whether 134 
FcγRI can play an effector role in inflammatory autoimmunity, we subjected FcγRIonly and 135 
FcγRnull mice to the K/BxN passive serum transfer model of autoimmune rheumatoid arthritis 136 
(K/BxN PA) [31]. Transfer of K/BxN serum into wt mice induced inflammatory signs of arthritis, 137 
and an arthritic score which peaked at day 4-6 and remained elevated until day 10 following 138 
serum transfer (Fig.2A&B), yet the same volume transferred into FcγRIonly or FcγRnull mice did 139 
not induce arthritis. Histological assessment of ankle joints confirmed marked to severe arthritis 140 
in wt mice, and no microscopic signs of arthritis observed in either FcγRIonly or FcγRnull mice 141 
(Supplementary Fig.1A-F). Moreover, K/BxN serum transfer at a dose higher that which was 142 
sufficient to induce arthritis in FcγRIVonly mice [24] did not result in arthritis induction in 143 
FcγRIonly mice (Supplementary Fig.1G), indicating that FcγRI alone cannot induce significant 144 
cellular infiltration and inflammation associated with this K/BxN model of autoimmune 145 
rheumatoid arthritis. 146 
During experimental antigen-induced arthritis (EAIA), FcγRI-/- mice were reported to 147 
experience comparable joint swelling but a reduction in severe cartilage destruction compared to 148 
wt mice [11, 12]. Importantly, EAIA relies first on antigen uptake and presentation, a known 149 
functionality of FcγRI [13] on monocyte-derived dendritic cells, leading to the activation of 150 
antigen-specific T and B cells and to pathogenic antibody production, and thereafter to FcγR-151 
mediated effector functions. Antigen uptake and presentation is not required in the K/BxN 152 
passive arthritis model, as pathogenic antibodies are directly injected into the recipient mouse. 153 
Because the severity of K/BxN passive arthritis is not affected in FcγRI-/- mice [25], and because 154 
FcγRIonly mice are resistant to this arthritis model (this report), FcγRI evidently does not induce 155 
the required effector functions to engender arthritic symptoms after K/BxN serum transfer. If this 156 
inability extends also to the EAIA model, one may propose that the reduced severity of EAIA 157 
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observed in FcγRI-/- mice is attributable rather to reduced antigen uptake and presentation. 158 
Furthermore, the cardinal marker of cartilage destruction used in EAIA studies relies on the 159 
release of matrix metalloproteinases (MMPs) and the creation of neo-epitopes [11, 32]. Therefore 160 
although FcγRI does not mediate cell recruitment and joint inflammation in either of these 161 
arthritis models (Fig.2A and [11, 12]), it may contribute to reaction severity via local events in 162 
the tissue, i.e. MMP release and cartilage destruction. 163 
 164 
The K/BxN model of autoimmune rheumatoid arthritis relies on local generation of IgG-165 
immune complexes on the cartilage surface, that trigger the activation of FcγR-expressing cells. 166 
To determine if FcγRI can induce local inflammation in another context, we induced IgG-167 
immune complexes at another anatomical site, the airways, and examined the resulting alveolitis. 168 
The inflammatory response in wt mice is characterised in the bronchoalveolar lavage (BAL) by 169 
massive neutrophil infiltration, significant infiltration of Ly-6C+ monocytes, and damage to the 170 
airways with haemorrhage into the BAL 16h after challenge (Fig.2C) [26]. Neither FcγRnull mice 171 
nor FcγRIonly mice experienced significant local inflammation: only a mild neutrophil infiltration 172 
was observed in the absence of inflammatory monocytes and haemorrhage. Together, our data 173 
support the notion that FcγRI does not mediate significant immune cell recruitment and 174 
inflammation associated with IgG-immune complex deposition, but may contribute to reaction 175 
severity via local events in the tissue, as suggested by studies using FcγRI-/- mice [13, 14]. 176 
 177 
Local inflammatory reactions, such as that which drive autoimmune arthritis, require the 178 
activation of several cell populations including monocytes/macrophages and neutrophils. 179 
Systemic inflammatory reactions like severe hypersensitivity reactions, or anaphylaxis, can also 180 
proceed through pathways dependent on IgG and IgG receptors, yet symptoms may arise 181 
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following the activation of only one cell population, among monocyte/macrophages, neutrophils 182 
and basophils (reviewed in [5, 33]). FcγRI may participate in such reactions by its expression on 183 
monocyte/macrophages. Although FcγRI-/- mice were reported to experience mouse IgG2a-184 
induced passive systemic anaphylaxis (PSA) with reduced severity [11], we could not reproduce 185 
these findings [34]. Here we demonstrate that FcγRIonly, like FcγRnull mice, were resistant to 186 
mouse IgG2a-mediated anaphylaxis (Fig.2D), heat-aggregated human IVIG-mediated 187 
anaphylaxis (Fig.2E) and even to an active model of anaphylaxis induced by BSA immunization 188 
and challenge (Supplementary Fig.3). Two possibilities emerge from these findings: firstly, that 189 
FcγRI alone is incapable of triggering sufficient inflammatory mediator release to cause systemic 190 
symptoms; secondly, that FcγRI expression is insufficient when expressed only on 191 
monocyte/macrophages to mediate anaphylaxis induction. 192 
 193 
Since we found that FcγRI is not sufficient to mediate IgG-induced local or systemic 194 
inflammation that require cell recruitment and activation, and release of mediators, we wondered 195 
if FcγRI was able to induce IgG-mediated cell depletion through phagocytosis and/or ADCC 196 
mechanisms that contribute to several autoimmune diseases (e.g. autoimmune thrombocytopenia 197 
and anaemia) and to immunotherapies. Earlier studies using FcγRI-/- mice indicated that FcγRI 198 
contributes to experimental autoimmune haemolytic anaemia induced by RBC-targeting mIgG2a 199 
antibodies [11], particularly to more severe manifestations at high Ab doses [35]. To determine if 200 
FcγRI has autoimmune destructive properties in FcγRIonly mice, we examined another model of 201 
autoimmunity characterised by circulating immune complexes, immune thrombocytopenic 202 
purpura (ITP) induced by injecting anti-platelet antibodies intravenously. ITP could be induced in 203 
wt and FcγRIonly mice, but not FcγRnull mice (Fig.3A). Within 4 hours of mAb injection, 204 
circulating platelet levels were reduced to <20% of their initial concentration in both wt and 205 
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FcγRIonly mice (Fig.3A&B), and platelet counts remained low even 24 hours later. Administration 206 
of platelet-targeting mAb at a threefold-reduced dose was also sufficient to induce platelet 207 
clearance in FcγRIonly mice, comparable to that of WT mice (Supplementary Fig.4A&B). High-208 
dose toxic clodronate-containing liposomes, administered i.v. to deplete monocyte/macrophages 209 
mainly in the blood, spleen, and liver, protected against ITP induction in both WT and FcγRIonly 210 
mice (Fig.3C), indicating that monocytes and macrophages are responsible for platelet clearance. 211 
 212 
To investigate the organ-specific macrophage population responsible for FcγRI-dependent 213 
autoimmune platelet clearance, we subjected FcγRIonly mice to either removal of the spleen 214 
(splenectomy), or partial removal of the liver (hemi-hepatectomy), prior to ITP induction (Figure 215 
3D&E). ITP induction in FcγRIonly mice was mildly inhibited by splenectomy (Figure 3D): 216 
comprising an average reduction in platelet clearance from 88% (±4.2%) to 77% (±9%) 3.5 hours 217 
after mAb injection. Splenectomised FcγRIonly and WT mice had somewhat elevated platelet 218 
counts at baseline, whether sampled 1 week or 3 weeks post-surgery, yet notably spleen removal 219 
did not inhibit ITP induction in WT mice (Supplementary Fig 4C, and data not shown). These 220 
findings suggest that splenic macrophages have a minor contribution to FcγRI-dependent ITP. 221 
Conversely, partial removal of the liver, which amounted to about 50% reduction in liver mass 222 
[36], did not affect ITP induction in FcγRIonly mice (Figure 3E and Supplementary Fig 4F), 223 
suggesting that liver macrophages may not be mandatory for FcγRI-dependent ITP. We 224 
performed ITP experiments starting 4-5 days after hepatectomies or sham surgeries, due to the 225 
rapid regenerative potential of the liver. Importantly, despite the inflammatory effect of the 226 
surgical procedures, we did not see differences in FcγRI expression on circulating cells between 227 
sham operated and hemi-hepatectomised mice (data not shown). It is difficult to completely 228 
exclude a role for the liver in this model, as the part of the organ remaining after hemi-229 
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hepatectomy may be sufficient to efficiently mediate ITP. Moreover, considerable platelet 230 
clearance was still observed in splenectomised mice, which implies the involvement of another 231 
physiological site; potentially blood monocytes [37]. Collectively, our data indicate a minor 232 
contribution of splenic macrophages to FcγRI-dependent ITP, but do not provide evidence of a 233 
role for liver macrophages. 234 
 235 
Antibody-mediated therapies are now a frontline treatment for many malignancies, 236 
including a number of autoimmune diseases. Reports using FcγRI-/- mice suggest that FcγRI 237 
contributes to IgG-induced tumour cell depletion in the lung [15] and liver [16] but not the skin 238 
[20]. As the latter finding may be due to redundant functions among mouse FcγRs in the skin, we 239 
followed TYRP-1+ Luc2+ B16 melanoma cells tumour growth by bioluminescent imaging in vivo 240 
[17] in mice treated or not with anti-TYRP-1 mouse IgG2a TA99 mAb. Identical growth kinetics 241 
were detected in FcγRIonly and FcγRnull mice (Fig.2F; WT mice in Supplementary Fig.5A), and 242 
repeated TA99 injections dramatically reduced tumour load in FcγRIonly mice, but not in FcγRnull 243 
mice, to that of background levels (Fig.4A and Supplementary Fig.5). Thus FcγRIonly mice reveal 244 
FcγRI-mediated functions that can remain masked in FcγRI-/- mice. Furthermore, these data 245 
reinforce the previously reported anti-tumour effector function of FcγRI in lung and liver tissues 246 
[15-18] and extends it to the skin tissue. 247 
 248 
Anti-CD20 therapy to deplete B cells has been highly successful in the treatment of B cell 249 
malignancies and autoimmune disorders. B cell depletion is known to depend on FcR-dependent 250 
mechanisms [38], primarily phagocytosis by Kupffer cells in the liver [36]. A role for FcγRI in 251 
the clearance of both malignant and endogenous B cells, in cooperation with FcγRIII and 252 
FcγRIV, has been suggested by several studies [18, 39], but has not been formally demonstrated. 253 
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Since FcγRI was sufficient to mediate destructive platelet clearance (Fig.3), and is expressed on 254 
liver Kupffer cells, we tested the capacity of FcγRI to deplete endogenous B cells in a model of 255 
anti-CD20 therapy. Administration of mouse CD20-targeting mAb 5D2 (IgG2a) induced B cell 256 
depletion in the blood, spleen and lymph nodes of FcγRIonly, but not FcγRnull mice. 16 hours after 257 
treatment 85% of B cells were cleared from the blood and 25-30% of B cells from the secondary 258 
lymphoid organs of anti-CD20 treated FcγRIonly mice. These data demonstrate that FcγRI, in the 259 
absence of FcγRIII and FcγRIV, is sufficient to mediate endogenous B cell clearance, and 260 
support a contribution for FcγRI to the efficacy of anti-CD20 therapy in models of lymphoma 261 
and autoimmunity. 262 
 263 
In conclusion, genetically modified FcγRIonly mice enabled us to demonstrate that the 264 
mouse high-affinity IgG receptor FcγRI is sufficient to mediate IgG-induced autoimmune 265 
thrombocytopenia and IgG-based immunotherapy targeting either B cells (anti-CD20) or 266 
subcutaneous melanoma, in the absence of FcγRIIB, FcγRIII and FcγRIV. FcγRI alone is, 267 
however, insufficient to induce IgG-induced autoimmune rheumatoid arthritis, airway 268 
inflammation and systemic anaphylaxis, probably due to its inability to efficiently mediate Ab-269 
induced cell recruitment or release of inflammatory mediators. Rather we identify that FcγRI 270 
mediates Ab-induced cell depletion/destruction, in both pathogenic autoimmune and therapeutic 271 
anti-tumour contexts; which agrees with the important contributions of this receptor to pathogen 272 
elimination [11, 40, 41] and antigen uptake and presentation [13]. Furthermore, our data attribute 273 
FcγRI-dependent phagocytic function to macrophages in the skin and the spleen. Finally, the 274 
effector capabilities of mouse FcγRI appear aligned with its restricted expression profile: low to 275 
moderate expression on monocytes, tissue macrophages and monocyte-derived DCs, who are 276 
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indeed responsible for clearance of foreign bodies and antigen uptake, whereas that of its human 277 
homolog hFcγRI extend to pro-inflammatory and pro-anaphylactic functions attributable to more 278 
promiscuous expression, particularly high on circulating monocytes and neutrophils. In 279 
conclusion, mice models expressing only one particular IgG receptor, e.g. FcγRIonly or FcγRIVonly 280 
mice [17, 22-24], are particularly useful to ascribe independent functions to FcγRs, as distinct 281 
from potential cooperative roles with other FcγR, the latter of which may be implied from studies 282 
using specific FcγR-/- mice. 283 
 284 
  285 
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FIGURE LEGENDS 433 
 434 
Figure 1: FcγRI only mice have normal blood leukocyte composition and show comparable 435 
FcγRI expression to that of WT mice. (A) Schematic representation of WT, FcγRIonly and 436 
FcγRnull mice. (B) Leukocyte counts and relative percentages of immune cell populations in the 437 
blood of WT (n=20), FcγRIonly (n=35) and FcγRnull (n=24) mice were enumerated using an 438 
automatic blood cell analyser. (C) Representative flow cytometry profiles of FcγRI expression on 439 
indicated cell populations from the blood and organs of WT, FcγRIonly and FcγRnull mice (MΦ; 440 
macrophages). Shaded histograms indicate background staining of a mIgG1 isotype control. 441 
Staining is representative of at least 2 independent experiments, n≥2. 442 
 443 
Figure 2: FcγRI alone is insufficient to mediate IgG-induced arthritis, airway inflammation 444 
or systemic anaphylaxis, (A-B) Arthritis was evaluated by clinical score (A) and ankle thickness 445 
(B) measured following transfer of K/BxN serum (5µL/g body weight) into WT (triangles), 446 
FcγRIonly (circles) or FcγRnull (squares) mice. (A) *p<0.05 on d3-6, WT compared to FcγRnull 447 
mice; (B) *p<0.05 on d2, **p<0.01 on d3, ***p<0.001 on d4-6, WT compared to FcγRnull and 448 
FcγRIonly mice. Data is representative of >2 independent experiments, n≥3 per group. (C) 449 
Bronchoalveolar lavage (BAL) was performed on naive (open symbols, n=3 per group) WT 450 
(triangles), FcγRIonly (circles) and FcγRnull (squares) mice, or mice 16-18h after challenge with 451 
antiserum i.n. and OVA antigen i.v. (closed symbols). Neutrophils and Ly6C+ macrophages 452 
(MΦ) in the BAL were determined by flow cytometry. Haemorrhage was determined by 453 
measuring haemoglobin concentration in the BAL supernatant. **p<0.01, *** p<0.001, **** 454 
p<0.0001; challenge data is pooled from 2 independent experiments, n=8-10 mice per group. (D-455 
E) Temperature monitoring during passive systemic anaphylaxis (PSA) in WT, FcγRnull or 456 
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FcγRIonly mice, induced by (D) mIgG2a anti-TNP sensitization and TNP-BSA i.v. challenge or 457 
(E) i.v. injection of aggregated human IVIG.  n=3-5 per group; data is representative of 2 458 
independent experiments. *p<0.05, **p<0.01, **** p<0.0001 at all time points from 30min; WT 459 
compared to FcγRnull and FcγRIonly mice.  460 
 461 
Figure 3: FcγRI-mediated thrombocytopenia is dependent on monocyte/macrophages, and 462 
partially inhibited by splenectomy. (A-B) Circulating platelets in the blood of WT (n=3), 463 
FcγRIonly (n=7) and FcγRnull (n=7) mice were quantified at baseline and following i.v. injection of 464 
10µg anti-platelet mAb (clone 6A6) and are represented as (A) percentage over time and (B) 465 
number of platelets 4 hours after mAb injection; **** p<0.0001 at 4h, 9h and 24h, WT vs 466 
FcγRnull and FcγRIonly vs FcγRnull. (C) Platelet counts at baseline and 4 hours after mAb injection 467 
in mice pre-treated with PBS- (open symbols) or toxic- (closed symbols) liposomes; n=4-5 per 468 
group; * p<0.05, **** p<0.0001, significance values indicated for each group at 4 hours 469 
compared to baseline. (D-E) ITP induction and percentage of circulating platelets in (D) FcγRIonly 470 
mice following splenectomy (closed symbols, n=11) compared to controls (open symbols, n=10); 471 
and (E) FcγRnull mice (n=4) or FcγRIonly mice following hemi-hepatectomy (n=5), compared to 472 
sham operated (n=4), or controls (n=3); ** p<0.01, splenectomised mice compared to controls; 473 
**** p<0.0001 at 3.5h, 8h and 24h, all groups compared to FcγRnull; ns not significant. Data in 474 
(D&E) is pooled from two independent experiments. 475 
 476 
Figure 4: FcγRI is sufficient for anti-melanoma and B cell depletion therapies. 477 
(A) FcγRIonly (circles) or FcγRnull (squares) mice were injected with B16-Luc2+ cells s.c. on d0 478 
and received no treatment (open symbols) or mAb TA99 i.v. on day 1, 2 and 3 (closed symbols); 479 
tumour growth was monitored by bioluminescent signal after s.c. injection of luciferin. 480 
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(B) FcγRIonly (circles) or FcγRnull (squares) mice were injected with anti-CD20 mAb 5D2 (closed 481 
symbols) or vehicle (open symbols). The percentage of remaining CD19+B220+ B cells 482 
(compared to the average of vehicle-treated controls) was determined in the blood, spleen and 483 
inguinal lymph nodes after 16h later. Data in (A) is representative of 2 independent experiments, 484 
n=4-5 per group. Data in (B) is pooled from 2 independent experiments, n=3-5 per group. 485 
*p<0.05 on day 7 and day 13, ***p<0.001, ****p<0.0001, FcγRIonly controls compared to mAb-486 
treated; ns not significant, FcγRnull controls compared to mAb-treated. 487 
 488 
Supplemental Materials and Methods 
 
Reagents 
Human IVIG (Gamunex®) was from Grifols, containing 63% hIgG1, 29% hIgG2, 5% 
hIgG3 and 3% hIgG4. B16-Luc2+ cells were from Caliper-Life Sciences. IgG were 
purified by Protein G-affinity purification from supernatants of hybridomas producing 
anti-gp75 mAb (TA99) from American Type Culture Collection, mIgG2a anti–
platelet mAb (clone 6A6) provided by Dr R. Good (USFCM, Tampa, FL, USA), and 
mIgG2a anti-TNP mAb (Hy1.2) provided by Shozo Izui (University of Geneva, 
Geneva, Switzerland). Luciferin was from Invitrogen, rabbit anti-OVA antiserum, 
OVA, BSA, and Freund’s adjuvant (CFA/IFA) were from Sigma-Aldrich, TNP(21-31)-
BSA was from Santa Cruz and PBS- and clodronate-liposomes were prepared as 
previously described [1]. Vivotag-680 was from Perkin Elmer and OVA-vivotag-680 
was prepared as recommended by the manufacturer.  
 
Tissue processing and flow cytometry 
Spleens were dissociated through a 70µm cell strainer into MACS buffer (PBS 
/0.5%BSA /2mM EDTA) and RBC lysis was performed using an ammonium 
chloride-based buffer. For isolation of skin cells, ears were split into dorsal and 
ventral halves and roughly chopped before digestion with 0.25mg/mL Liberase TL 
ResearchGrade (Roche) + 0.1mg/mL DNase (Sigma) for 1h at 37°C (800rpm; 
Eppendorf Thermomixer), washed with 10x volume of PBS/ 10%FBS /2mM EDTA 
and processed through a 100µm cell strainer. Livers were perfused with cold PBS 
before dissection, and liver leukocytes were isolated using the Liver Dissociation Kit 
and gentleMACS Octo Dissociator from Miltenyi, according to the manufacturer’s 
instructions. Cells were isolated from the peritoneum by lavage with 6mL cold PBS; 
BALs were performed 3x with 1mL PBS. For blood leukocyte analysis, heparinised 
blood was subjected to RBC lysis with either Red Blood Cell Lysis Solution 
(Miltenyi) or BD Pharm Lyse Lysing Buffer (BD Biosciences) and washed with 
MACS buffer. Single cell suspensions were washed with MACS buffer, incubated 
with 2.4G2 (Fab’)2 fragments (anti-CD16/32, 40µg/mL; 15min on ice) and stained 
with fluorochrome-conjugated antibodies in MACS buffer for 30min on ice. Data was 
collected on a MACSQuant flow cytometer (Miltenyi), and analysed using FlowJo 
Software (TreeStar, Inc.). 
Cell populations were defined by FSC/SSC properties and surface markers as 
indicated (Fig.1B), or in the BAL (Fig.2B): alveolar macrophages (CD11c+/ SiglecF+), 
eosinophils (CD11cneg/ SiglecF+), neutrophils (CD11cneg/ SiglecFneg/ CD11b+/ Ly-
6G+), Ly-6C+ macrophages (CD11cneg/ SiglecFneg/ CD11b+/ Ly-6Gneg/ Ly-6C+). 
 
Active Systemic Anaphylaxis (ASA) 
Mice were immunised i.p. on d0 with 200µg BSA in Complete Freund’s Adjuvant, 
and boosted on d14 with 200µg BSA in Incomplete Freund’s Adjuvant. BSA-specific 
IgG1, IgG2a/b/c and IgE serum antibodies were titered by ELISA on d21 as described 
[2]. Mice with comparable antibody titers were challenged 13-14 days after the last 
immunisation i.v. with 500µg BSA. Central temperature and mortality was monitored. 
 
Partial hepatectomy and splenectomy 
Partial hepatectomy was perfomed as described[3]. Mice were anaesthetised and a 
transverse abdominal incision was made. The superior lobes of the liver were laid on 
the diaphragm and the ligaments of the caudate lobe dissected. The caudate lobe was 
then pulled in front of the stomach and resected after in-bloc ligature of its hilum (6/0 
silk). The lateral left lobe was resected using the same technique. The abdomen was 
closed using 4/0 silk running sutures. The procedure removed approximately half of 
the initial liver mass. Mice were rested for 2 days before experimental procedure. 
For splenectomy, a small vertical incision was made on the left flank, the spleen was 
gently pulled outside the abdomen, and the splenic ligaments and vessels were cut. 
The abdomen was closed with a 4/0 silk suture, and the skin with a surgical staple. 
Mice were rested for 1-3 weeks before experimental procedure. 
 
Histology 
Ankle joints and surrounding tissues (from the extremity of the femur/tibia to the 
digits) were sampled on day 8 after K/BxN serum transfer (batch #1, 5mL/kg), then 
fixed and simultaneously decalcified using Formical-4® (StatLab Medical Products) 
for 2 weeks. Samples were routinely embedded in paraffin, and 4 mm sections were 
stained with haematoxylin and eosin (H&E). Sections were evaluated microscopically 
and histological changes (i.e. inflammation, pannus formation, bone erosion and 
cartilage damage) were scored from 0 (no change) to 5 (severe). 
 
Supplemental references 
[1] Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: 
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Methods, 1994;174:83-93. 
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N et al. Mouse and human neutrophils induce anaphylaxis. J Clin Invest, 
2011;121:1484-96. 
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Supplementary Figure 1
6XSSOHPHQWDU\)LJXUHP)FȖ5,DORQHLVLQVXIILFLHQWWRLQGXFHDUWKULWLVHYHQZLWKLQFUHDVHG
GRVHRIDGPLQLVWUDWLRQRUDGLIIHUHQWEDWFKRI.%[1VHUXP(A-F) H&E stained paraffin-
embedded sections of decalcified ankle joints on day 8 after K/BxN serum transfer (batch #1,
5mL/kg). Histological signs of marked to severe arthritis were noted in WT mice (A, D), and were
characterised by neutrophil and mononuclear cell infiltrates (arrow), pannus formation (asterisk),
cartilage damage and bone resorption (arrowhead). No microscopic signs of arthritis were observed
LQ)FȖ5null%(RU)FȖ5,only (C, F) mice. (b: bone; c: synovial cavity, s: synovial membrane). Scale
bar: (A, B, C) 500 µm, (D, E, F) 100 µm (G) Arthritic score and ankle thickness following transfer of
KLJKGRVH.%[1VHUXPEDWFKP/NJLQWR:7WULDQJOHV)FȖ5nullVTXDUHVRU)FȖ5,only
(circles) mice, or (H) arthritic score following transfer of K/BxN serum (batch #2, indicated volumes)
LQWR:7RU)FȖ5,only mice. 
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Supplemental Figure 2: FcγRI binds OVA immune complexes. CHO cells stably
transfected to express FLAG-tagged mFcγRI, mFcγRIIB, mFcγRIII, or mFcγRIV, as indicated,
or control cells (-) were stained with an anti-FLAG antibody (upper panel) to confirm receptor
expression; shaded histograms represent isotype control staining. CHO transfectants were
incubated with immune complexes (ICs) formed by rabbit anti-OVA serum and fluorescently
(vivotag680)-tagged OVA (lower panel). Shaded histograms represent background
fluorescence (OVA-vivotag680 alone); open histograms IC binding.
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Fc Rnull Fc RIonly 
Maximum 
temp. loss 
IVIG 
PSA 
BSA 
ASA 
IVIG 
PSA 
BSA 
ASA 
<1°C 56 (100%) 14 (100%) 67 (82,7%) 36 (83,7%) 
1-2°C 0 0 6 (7,4%) 5 (11,6%) 
>2°C 0 0 8 (9,9%) 2 (4,7%) 
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BSA-ASA BSA-ASA 
only mice are resistant to BSA-ASA and IVIG-PSA, 
 at a low-dose of platelet-targeting Ab. (A) 
only (right) mice were injected with 1mg heat-aggregated 
 and challenged with BSA antigen (BSA-ASA) and 
monitored. Bottom: Table summarises individual values 
and graphs represent mean ± SEM. Data is pooled from >4 individual experiments. 
(B) Platelet counts in Fc Rnull and Fcnd only mice 4h after injection of 3µg anti-platelet 
mAb 6A6.!
Supplementary Figure 3: FcγRIonly mice are resistant to BSA-ASA and IVIG-PSA.
(A) FcγRnull(left) and FcγRIonly (right) mice were injected with 1mg heat-aggregated
IVIG (IVIG-PSA) or immunized and challenged with BSA antigen (BSA-ASA) and
central temperatures were monitored. Only a small percentage of FcγRIonly animals
across all experiments demonstrated a mild hypothermia. Table summarises
individual values and graphs represent mean ± SEM. Data is pooled from >4
individual experiments.
Supplementary Figure 4: FcγRIonly and WT mice are susceptible to thrombocytopenia at
a low-dose of platelet-targeting Ab; platelet clearance is partially inhibited by splenectomy but
not affected by hemihepatectomy. Circulating platelets were quanitifed in the blood of (A-B) WT,
FcγRIonly and FcγRnull mice at baseline and after injection of 3μg anti-platelet mAb 6A6, and are
represented as (A) percentage over time and (B) number of platelets 4 hours after mAb injection.
n=5-6 per group; **** p<0.0001 at 4, 12 and 24 hours. (C-D) Number of platelets in the blood of WT
or FcγRIonly controls, sham operated, or mice with splenectomy (C) or hemihepatectomy (D), at baseline
(1 week after splenectomy or 2 days after hemihepatectomy or sham) and 3,5 hours after 10μg mAb
6A6. (C) n=4-5 per group, data shown from one of two experiments; ** p<0.01. (D) n=3-5 per group,
data pooled from two independent experiments; **** p<0.0001.
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Supplemental Figure 5: mFcγRI alone is sufficient to mediate mAb therapy of subcutaneous
melanoma. Mice were injected subcutaneously with B16-Luc2+ melanomas cells with or without
therapeutic mAb TA99 treatment and (A,C) tumour growth was monitored by bioluminescent signal
10min after s.c. luciferin injection at indicated timepoints or (B) tumour size measured on day 12.
(A)Tumour growth is comparable between untreated WT (triangles, n=5) and FcγRIonly (circles,
n=5 until d7, n=3 at d12) mice. (B-D) FcγRIonly mice eliminate tumours with TA99 treatment, and
FcγRnull mice do not. (D) Representative photographs taken at day 16. (B-D) correspond to the
experiment shown in Figure 2F and are representative of 2 individual experiments.
